

1/31

Fig.1A.







Fig.1B.




2/31


Fig.2.



3/31



4/31



5/31

Fig.4A.





Fig.4B.



6/31

Fig.4C.






Fig.4D.



7/31



Notes:

- This Strategy can be applied to reformatting of an individual Fab and to a mixture of different clones.
- $Asc1^*$: For technical reasons the internal fragment contains as "Asc1-compatible" $Mlu1$ site; $Asc1$ and $Mlu1$ recognition sequences are destroyed.

8/31

Fig.6A.






Fig.6B.



9/31

Fig.6C.



10/31

Fig.7A.





Fig.7B.



11/31

Fig.8A.






Fig.8B.




12/31

Fig.9A.

M27E11 IgG (with competition)
on bCTD, detection a-myc and r-a-mHRP

**Fig.9B.**

M28B2 IgG (with competition)
on bCTD, detection a-myc and r-a-mHRP



13/31

Fig.9C.

Control antibodies (with competition)
on bCTD, detection anti-mouse or anti-goat HRP







Fig.9D.

PH1 IgG (with competition)
on bCTD, detection a-myc and r-a-mHRP





14/31

Fig.10.





15/31

Fig.11A.



16/31

Fig.11 B.



17/31

Fig.12.






Fig.13.



18/31

Fig. 14.




19/31

Fig.15.

peptide 1:	biotin-GC-ARMEEMGSRTDRRLDE	aa	1-16(16+2	aa)
peptide 2:	biotin-GC-VKEQVAEVRAKLEEQA	aa	17-32(16+2	aa)
peptide 3:	biotin-GC-QQIRLQAEAFQARLKS	aa	33-48(16+2	aa)
peptide 4:	biotin-GC-WFEPLVEDMQRWAGL	aa	49-64(16+2	aa)
peptide 5:	biotin-GC-VEKVQAAVGTSAAPVP	aa	65-80(16+2	aa)
peptide 6:	biotin-GC-RTRDRLDEVKEQVAEV	aa	9-24(16+2	aa)
peptide 7:	biotin-GC-RAKLEEQAQQIRLQAE	aa	25-40(16+2	aa)
peptide 8:	biotin-GC-AFQARLKSWFEPLVED	aa	41-56(16+2	aa)
peptide 9:	biotin-GC-MQRQWAGLVEKVQAAV	aa	57-72(16+2	aa)
peptide 10:	biotin-GC-GTSAAPVPSDNH	aa	73-84(12+2	aa)


20/31

Fig.16.



21/31

Fig.17.



22/31

Fig.18.





Fig.19.



24/31

Fig.20.






Fig.21.




26/31

Fig.22.



27/31



28/31

Fig.24A.





Fig.24B.



29/31

Fig.25.




Fig.26.




Fig.27.

